Moneycontrol PRO
HomeAuthorViswanath pilla News

Viswanath Pilla

Senior Assistant Editor

Moneycontrol News

Telangana police arrest two in $250 million cyber-extortion case linked to Hetero Drugs

BUSINESS

Telangana police arrest two in $250 million cyber-extortion case linked to Hetero Drugs

The accused, identified as Gadi Manikanta and Yendapalli Jessy Sudarshan, allegedly impersonated USFDA officials using fake email IDs and encrypted messaging apps, including Signal, to pressure Hetero, a release issued by Cyberabad police said.

New generation drugs for cholesterol, fatty liver & kidney disease, and what they promise

HEALTH-AND-FITNESS

New generation drugs for cholesterol, fatty liver & kidney disease, and what they promise

These drugs promise faster results with fewer side effects, and in some cases, reversal or slows the disease progression.

Mankind Pharma hit by domestic slowdown, slow BSV synergy and GST 2.0, but margin guidance intact

BUSINESS

Mankind Pharma hit by domestic slowdown, slow BSV synergy and GST 2.0, but margin guidance intact

Mankind Pharma CEO Sheetal Arora has attributed the slowdown to GST 2.0 disruptions and uneven monsoon.

AstraZeneca partners with Sun Pharma to expand access to hyperkalaemia treatment Lokelma

BUSINESS

AstraZeneca partners with Sun Pharma to expand access to hyperkalaemia treatment Lokelma

Under the agreement, AstraZeneca will sell SZC under the brand Lokelma, while Sun Pharma will distribute it as Gimliand.

Biocon CEO sees USFDA draft rules potentially slashing biosimilar development costs by half

BUSINESS

Biocon CEO sees USFDA draft rules potentially slashing biosimilar development costs by half

Global biosimilar development typically costs between $100 million and $200 million, but the U.S. Food and Drug Administration’s updated recommendations aim to eliminate expensive comparative efficacy studies, relying instead on advanced analytical and pharmacokinetic data.

OneSource Specialty posts Rs 44.9 crore net profit

BUSINESS

OneSource Specialty posts Rs 44.9 crore net profit

Chief Executive Officer Neeraj Sharma said the performance was driven by master service agreements and sales from the company’s IP-led base business.

Eris Lifesciences net profit jumps 39 percent YoY to Rs 134 crore

BUSINESS

Eris Lifesciences net profit jumps 39 percent YoY to Rs 134 crore

Revenue rose 6.9 percent YoY to Rs.792 crore.

Biocon reports Rs 85 crore net profit in Q2FY26

BUSINESS

Biocon reports Rs 85 crore net profit in Q2FY26

Consolidated revenue grew 11% year-on-year to Rs. 4,389 crore, led by a 25% jump in biosimilars, which contributed 61% of segmental revenue.

Weight loss drug Wegovy to become cheaper as Novo Nordisk cuts prices by up to 37%

BUSINESS

Weight loss drug Wegovy to become cheaper as Novo Nordisk cuts prices by up to 37%

The company announced that the starting dose of Wegovy (0.25 mg) will now cost Rs 2,712 per week, down from Rs.4,336

Apollo Hospitals says on track for Rs 25,000-crore revenue ahead of FY27 IPO for omnichannel pharmacy & distribution arm

BUSINESS

Apollo Hospitals says on track for Rs 25,000-crore revenue ahead of FY27 IPO for omnichannel pharmacy & distribution arm

Backed by private equity firm Advent International, Apollo HealthCo—which combines offline pharmacy distribution, digital health services via Apollo 24/7, and the soon-to-be-merged Keimed—has seen a sharp turnaround in profitability.

Cough and cold medicine sales dip in October as syrup safety concerns mount

BUSINESS

Cough and cold medicine sales dip in October as syrup safety concerns mount

This marks the first time in three years that October volumes failed to surpass September, despite the onset of seasonal respiratory illnesses.

Novo Nordisk partners with Emcure to distribute weight loss drug semaglutide in India

BUSINESS

Novo Nordisk partners with Emcure to distribute weight loss drug semaglutide in India

The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access beyond metro cities and premium clinics.

DCGI signals end of grace period for small drugmakers, orders immediate inspections under revised Schedule M

BUSINESS

DCGI signals end of grace period for small drugmakers, orders immediate inspections under revised Schedule M

The directive from the DCGI, signals an end to the current extension of timeline until December 31, 2025 for thousands of small and medium-sized pharmaceutical firms to comply with the Revised Schedule M rules, warning that "strict action" will be initiated against units that fail to meet the new quality mandates.

Cipla's Next Chapter: Achin Gupta to succeed Umang Vohra as global CEO, faces innovation challenge

BUSINESS

Cipla's Next Chapter: Achin Gupta to succeed Umang Vohra as global CEO, faces innovation challenge

Gupta, currently the Global Chief Operating Officer, will serve as MD & Global CEO-designate starting January 1, 2026. Company executives describe him as Mr Cool and no stranger to innovation and licensing deals.

Lilly’s Mounjaro is India’s top-selling drug in October

BUSINESS

Lilly’s Mounjaro is India’s top-selling drug in October

The sales rose to nearly Rs 100 crore, a month-on-month growth of around 25%

Apollo Hospitals net profit zooms 26% to Rs 477 crore in Q2FY26

BUSINESS

Apollo Hospitals net profit zooms 26% to Rs 477 crore in Q2FY26

Revenue rose 13% YoY to Rs 6,304 crore, while EBITDA grew 15% to Rs 941 crore, with overall margins holding steady at 14.9%.

GSK India posts Rs 255 crore net profit in Q2FY26

BUSINESS

GSK India posts Rs 255 crore net profit in Q2FY26

Revenue from operations stood at ₹974 crore, reflecting a temporary topline dip due to GST-related transitions, seasonal disruptions, and a fire at a contract manufacturing site that impacted supply of select general medicines brands.

Sun Pharma backs speciality play, lines up launches in US amid uncertainty over tariffs

BUSINESS

Sun Pharma backs speciality play, lines up launches in US amid uncertainty over tariffs

Despite macro uncertainties, Sun Pharma has been bullish on its specialty pipeline and global expansion.

Syngene net profit drops 37% to Rs 67 crore in Q2FY26

BUSINESS

Syngene net profit drops 37% to Rs 67 crore in Q2FY26

“Our Q2 performance was driven by underlying revenue growth from research services which compensated for the anticipated inventory correction in biologics manufacturing,” said Peter Bains, Managing Director and CEO.

Piramal Pharma posts Rs 99 crore loss in Q2FY26 weighed down by CDMO business

BUSINESS

Piramal Pharma posts Rs 99 crore loss in Q2FY26 weighed down by CDMO business

The company attributed the loss to decline to inventory destocking by a key customer in a large on-patent CDMO order and slower order inflows amid inconsistent recovery in US biopharma funding.

Sun Pharma net profit rises 2.6%YoY to Rs 3,118 crore in Q2FY26

BUSINESS

Sun Pharma net profit rises 2.6%YoY to Rs 3,118 crore in Q2FY26

Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) geographies.

Gland Pharma net profit rises 12%YoY to Rs 183.7 crore in Q2FY26

BUSINESS

Gland Pharma net profit rises 12%YoY to Rs 183.7 crore in Q2FY26

Consolidated revenue rose 6% to ₹1487 crore, while EBITDA grew 6% to ₹313.9 crore.

Dr.Ajaikumar-backed Inviga Healthcare Fund picks up 21% stake in Forus Health

BUSINESS

Dr.Ajaikumar-backed Inviga Healthcare Fund picks up 21% stake in Forus Health

Forus Health, best known for its 3nethra series of eye screening devices, has screened over 22 million patients across 75 countries.

Wockhardt swings to profit in Q2, novel antibiotic Zaynich gets breakthrough status in Saudi Arabia

BUSINESS

Wockhardt swings to profit in Q2, novel antibiotic Zaynich gets breakthrough status in Saudi Arabia

Revenue for the quarter stood at ₹782 crore, up from ₹738 crore in Q1. EBITDA margins improved to 20.5%, up from 13.7% in the previous quarter.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347